The World Drug Safety Congress Americas 2024 will bring together more than 2,500 top leaders and stakeholders in biopharma to discuss the key challenges faced in pharmacovigilance (PV) and device safety.
TCS has been a proud Diamond Sponsor of this event since the last three years. Drop by Booth #613 to engage with our core PV leadership. Learn more about our deep PV transformation expertise and experience our purpose-built solution – TCS ADD™ Safety, an AI platform for pharmacovigilance.
TCS is part of multiple speaking sessions wherein speakers from the global Top 10 pharma companies will join us and share insights during the TCS-hosted keynote panel discussion. A track session with the theme ‘AI and machine learning’ is also lined up.
Do not miss out on these interesting discussions and POC story-sharing at the event!
Keynote panel discussion:
Title: The use of AI in pharmacovigilance
Date and time: October 29 | 4:15 PM to 4:55 PM ET
The TCS ADD™ Safety team, along with a panel of PV pharma leaders, will discuss the most recent advances in AI application in PV and adopting it with a scalable and safe program to maximize the efficiency of an AI-based PV platform.
The TCS ADD™ Safety platform has completed more than four years in the production environment. The team of experts will discuss fundamental topics, challenges, opportunities, and next-gen technology applications in PV along with real-life examples.
Engage with industry leaders during this keynote discussion.
Know more about TCS ADD™ Safety platform here.
Session:
‘AI and machine learning’ track session
Title: Next-generation PV – A discussion with expert leaders
Date and time: October 29 | 12:50 PM to 1:10 PM ET
The traditional PV model is not sustainable anymore to handle the volume and complexity of safety reports timely, thus compromising the safety and health of patients and consumers.
During the last five years, we have seen rapid advancements and the adoption of cognitive technologies. Though AI-based PV platforms have progressed, there are concerns about the quality of information and the accuracy with which these AI-ML platforms can interpret safety report data and justify decisions made by AI along with investments required for adopting these systems.
During this session, we will discuss how, despite the challenges, the AI-based PV platforms are becoming the new modalities in the life sciences industry.
Use the opportunity to engage with our experts during this interesting session.
